Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Ex Input:
Plunkett finished the game with 16 out of 25 pass completions for 172 yards and a touchdown. Theismann threw for more yards than Plunkett (243), but was just 16 out of 35 and was intercepted twice. He was also sacked six times. Branch was the top receiver of the game with six receptions for 94 yards and a touchdown. Guy punted seven times for 299 yards (42.7 average), with 244 net yards (34.8 average) and planted five of his seven punts inside the 20. Martin recorded a sack, a pass deflection, and a fumble recovery. Riggins, who had rushed for over 100 yards in his last six postseason games, was held to 64 yards and a touchdown on 26 carries, with his longest gain being just 8 yards. Brown was their top receiver with three receptions for 93 yards. Tight end Clint Didier caught five passes for 65 yards. Garrett recorded 100 yards on kickoff returns, and one reception for 17 yards. Part of both of Allens touchdown runs were cutbacks, which, according to New York Daily News writer Larry Fox, burned an overpursuing Redskins defense.

Ex Output:
Which player achieved more receptions, Branch or Brown?


Ex Input:
Tanezumab is a humanized monoclonal antibody that specifically inhibits nerve growth factor as a treatment for chronic pain. This phase IIB study investigated the efficacy and safety of tanezumab for chronic low back pain vs placebo and naproxen. Patients (N=1347) received intravenous tanezumab (5, 10, or 20mg every 8weeks), naproxen (500mg twice daily), or placebo. The primary efficacy end point was mean change in daily average low back pain intensity (LBPI) from baseline to week 16. Secondary end points included mean change from baseline to week 16 in the Roland Morris Disability Questionnaire and Patient's Global Assessment (PGA) of low back pain. Tanezumab 10 and 20mg had similar efficacy profiles and significantly improved LBPI, Roland Morris Disability Questionnaire, and PGA scores vs both placebo and naproxen (P.05). Tanezumab 5mg provided improvement of PGA scores vs placebo (P.05), and naproxen resulted in significant improvement of LBPI vs placebo (P.05). Adverse event incidence was comparable across tanezumab doses but higher than with placebo or naproxen. Arthralgia, pain in extremity, headache, and paresthesia were the most commonly reported adverse events by tanezumab-treated patients. The most frequently reported adverse events resulting in discontinuation of tanezumab treatment were arthralgia and paresthesia; the highest frequency was observed with tanezumab 20mg (both 1.4%). Serious adverse event incidence was similar across treatments. In conclusion, tanezumab provided significantly greater improvement in pain, function, and global scores vs placebo and naproxen in patients with chronic low back pain.

Ex Output:
What is the target of tanezumab?


Ex Input:
On 1 January 2016, Moustoir-Remungol, Naizin and Remungol merged becoming one commune called Evellys.

Ex Output:

By what was Moustoir-Remungol replaced?